Sunbird Bio raised $14 million in a funding series A led by Eli Lilly and Company and EDBI to advance its blood-based diagnostic platform for neurological disorders.

Oct 16, 2024•10 months ago

Amount Raised

$14 Million

Round Type

series a

CambridgeBiotechnology

Investors

S32Polaris PartnersClavyst BioEdbiEli Lilly And Company

Description

Sunbird Bio closed a financing round of $14 million to enhance its blood-based diagnostic platform aimed at improving the diagnosis and treatment of Alzheimer's and other neurological disorders. The funding will facilitate the expansion of clinical development and the opening of new laboratory space.

Company Information

Company

SunBird Bio

Location

35 CAMBRIDGEPARK DR.

Cambridge, Massachusetts, United States

About

Sunbird Bio is a leader in protein-based diagnostic tests, becoming the first company to overcome the challenge of accurately detecting and differentiating the specific proteins that aggregate, and therefore signal the presence of Alzheimer’s disease, with a simple blood draw. We are addressing the tremendous, growing need for more reliable and sensitive diagnostic tests to accelerate drug development and enhance patient care.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends